Redwood Pharma AB engages in the development, production, and marketing of opthalmic pharmaceuticals. Its products include RP501 and RP101. The company was founded by Martin Vidaeus, Hans Ageland, and Charles P. du Mée on January 20, 2012 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company